Group 1 - Company GFH375 has shown promising results in treating KRAS G12D mutation pancreatic ductal adenocarcinoma (PDAC) patients, with a 40.7% objective response rate and a 96.7% disease control rate in a study presented at the ESMO annual meeting [1] - The median progression-free survival was reported at 5.52 months, with a 92.2% overall survival rate at 4 months for patients treated with GFH375 [1] - The KRAS G12D mutation is prevalent, affecting nearly 30% of KRAS mutations, indicating a significant unmet clinical need in the patient population [2] Group 2 - GFH375 has received FDA fast track designation and is approved for I/II clinical trials, targeting both first-line and subsequent treatments for locally advanced and metastatic KRAS G12D mutation PDAC patients [2] - The drug is a highly selective small molecule KRAS G12D inhibitor that disrupts the activation of downstream pathways, effectively inhibiting tumor cell proliferation [2] - A collaboration agreement has been established between the company and Verastem for the development of three RAS/MAPK-driven cancer products, with GFH375 being the lead project [3]
劲方医药-B：KRAS G12D抑制剂GFH375治疗晚期胰腺导管腺癌研究数据呈列于2025年ESMO年会口头报告及突破性研究摘要